BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1688253)

  • 21. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
    Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
    Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of five tumor marker assay in patients with lung cancer.
    Mizushima Y; Tsuji H; Izumi S; Hirata H; Kin Y; Kawasaki A; Matsui S; Yano S
    Anticancer Res; 1991; 11(1):91-5. PubMed ID: 2018388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
    Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
    Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
    Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
    Buccheri G; Ferrigno D
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
    Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
    Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical evaluation of TPA-assay kit using monoclonal antibodies].
    Saga T; Sakahara H; Kousaka T; Yao Z; Nakamoto Y; Hattori N; Zhang M; Nakayama M; Ohshio G; Imamura M; Konishi J
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):615-21. PubMed ID: 8678521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The concentration of carcinoembryonic antigen and carbohydrate antigen Ca-19-9 in the blood serum in cancerous diseases of the gastrointestinal tract].
    Mit'kov VV; Ogneva TV; Goriaĭnova II; Milanov S; Milkov V
    Med Radiol (Mosk); 1989 Nov; 34(11):22-4. PubMed ID: 2586258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
    Willsher PC; Beaver J; Blamey RW; Robertson JF
    Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
    Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
    Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].
    Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L
    Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.